Summary of Study ST001469

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000993. The data can be accessed directly via it's Project DOI: 10.21228/M8BH7T This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST001469
Study TitleMetabolomics of lung injury after allogeneic hematopoietic cell transplantation - Lung DI-FTMS
Study Typepreliminary data
Study SummaryAllogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment option for a variety of hematological malignancies. Interactions between the donor immune system and the patient tissue result in a disease, called GVHD. The pathophysiology of acute GVHD can be hypothesized in three sequential phases: cytokine storm and activation of the antigen-presenting cells (APC), donor T cell activation and effector cell phase. Idiopathic pneumonia syndrome (IPS) is one of the most deleterious complications after allogeneic HCT and is considered not only to be related to conditioning regimen toxicity but also represents an end organ damage caused by allo-reactive T cells, therefore making the lung susceptible to a two-pronged attack, one of which overlaps with GVHD causing other target organ injury. IPS results in mortality of up to 90% of patients. We will use a murine model of IPS and GVHD which is well established in our group, and in which disease evolves either across disparities in major histocompatibility complex (MCH) class I and II, minor histocompatibility antigens (miHags) or both. Metabolomics changes following syngeneic and allogeneic HCT at post-transplantation Days +7 (cytokine storm phase) and Days +42 (cellular effector phase) are compared to baseline wild-type (naive) controls. Prior to analysis, naïve - and experimental mice (N=3 from each group) were fed with semi-liquid diet supplemented with tracers (13C6-glucose ) over 24 hours. At the end of 7 days or 42 days, respectively, feces and aGVHD target organs (colon, liver and lung) were collected from all groups and further processed and / or analyzed. We expect to reveal metabolic pathways affected after allo-HCT which contribute to immune cell mediated lung injury (IPS) and will potentially identify different metabolic pathways in other GVHD target organs.
Institute
University of Kentucky
DepartmentMCC
Last NameHildebrandt
First NameGerhard
AddressCTW-453, 900 South Limestone street. UKY. Lexington, Kentucky-40536
Emailgerhard.hildebrandt@uky.edu
Phone800-333-8874
Submit Date2020-08-22
Raw Data AvailableYes
Raw Data File Type(s)raw(Thermo)
Analysis Type DetailLC-MS
Release Date2020-09-10
Release Version1
Gerhard Hildebrandt Gerhard Hildebrandt
https://dx.doi.org/10.21228/M8BH7T
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:


Combined analysis:

Analysis ID AN002445
Analysis type MS
Chromatography type None (Direct infusion)
Chromatography system None
Column None
MS Type ESI
MS instrument type FTMS
MS instrument name Orbitrap Fusion
Ion Mode POSITIVE
Units peak_height

MS:

MS ID:MS002268
Analysis ID:AN002445
Instrument Name:Orbitrap Fusion
Instrument Type:FTMS
MS Type:ESI
MS Comments:Measurements made using direct infusion (nano-electrospray) FTMS.
Ion Mode:POSITIVE
  logo